Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of palonosetron (PALO) plus dexamethasone for chemotherapy-induced nausea and vomiting in pediatric patients
jRCT2080223250Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Efficacy of palonosetron for CINV including delayed phase. Started Jun 2016; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080223250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223250.